Yaşa Dilek, Ağca Alper
Beyoğlu Eye Research and Training Hospital, Bereketzade Mah, No. 2, Beyoglu, Istanbul, Turkey.
J Ophthalmol. 2018 Sep 30;2018:4210460. doi: 10.1155/2018/4210460. eCollection 2018.
To compare refractive stability, central endothelial cell density (ECD), and complications between Verisyse (Abbott Medical Optics, Netherlands) and Veriflex (Abbott Medical Optics, Netherlands) phakic intraocular lenses (pIOL) over five years.
We retrospectively reviewed the medical records of patients who underwent Verisyse or Veriflex pIOL implantation for surgical correction of myopia. Patients with a 5-year follow-up period were included in the study. Uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), spherical equivalent of manifest refraction (SE), and ECD were compared between the groups preoperatively and 1, 3, and 5 years postoperatively.
The study included 47 eyes in the Verisyse group and 50 eyes in the Veriflex group. There was no significant difference in mean SE, UDVA, CDVA, and ECD preoperatively or postoperatively. In both groups, there was a statistically significant myopic shift between 1-year and 5-year visits (-0.25 ± 0.30 D and -0.23 ± 0.48 D in the Verisyse and Veriflex groups, respectively). There was no significant difference between the groups in terms of efficacy and safety indexes at 5 years. ECD loss was highest during the first year (3.9% loss in the Verisyse group and 3.9% loss in the Veriflex group, =0.670). At 5 years, the mean cumulative ECD losses in the Verisyse and Veriflex groups were 7.42% and 7.64%, respectively (=0.709). Cataracts developed in 2.1% of the eyes in the Verisyse group and in 2.0% of those in the Veriflex group. No sight-threatening complications were observed.
Verisyse and Veriflex pIOLs are highly effective for treating high myopia up to 5 years after surgery. Longitudinal studies with longer follow-up periods are necessary to determine the endothelial safety profile.
比较Verisyse（荷兰雅培医疗光学公司）和Veriflex（荷兰雅培医疗光学公司）有晶状体眼人工晶状体（pIOL）在五年内的屈光稳定性、中央内皮细胞密度（ECD）及并发症情况。
我们回顾性分析了接受Verisyse或Veriflex pIOL植入术以手术矫正近视患者的病历。纳入研究的患者随访期为5年。比较两组术前以及术后1年、3年和5年时的未矫正远视力（UDVA）、矫正远视力（CDVA）、明显屈光的等效球镜度（SE）和ECD。
研究包括Verisyse组47只眼和Veriflex组50只眼。术前及术后平均SE、UDVA、CDVA和ECD均无显著差异。两组在1年和5年随访时均有统计学意义的近视漂移（Verisyse组为-0.25±0.30D，Veriflex组为-0.23±0.48D）。两组在5年时的疗效和安全性指标无显著差异。ECD损失在第一年最高（Verisyse组损失3.9%，Veriflex组损失3.9%，P=0.670）。5年时，Verisyse组和Veriflex组的平均累积ECD损失分别为7.42%和7.64%（P=0.7�9）。Verisyse组2.1%的眼发生白内障，Veriflex组2.0%的眼发生白内障。未观察到威胁视力的并发症。
Verisyse和Veriflex pIOL在手术后长达5年的时间里对治疗高度近视非常有效。需要进行更长随访期的纵向研究以确定内皮安全性情况。
